Filing Flows › Collegium Pharmaceutical (COLL) › Belbuca revenue
Collegium Pharmaceutical (COLL) Belbuca revenue by quarter
Collegium Pharmaceutical's Belbuca revenue was $57.7M in Q3 2026 (third quarter 2026), +0.1% from Q2 2026. Over the last 6 quarters it ranged from $51.7M (Q1 2025) to $58.3M (Q3 2025).
| Quarter | Belbuca revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $57.7M | +0.1% | -0.9% |
| Q2 2026 | $57.7M | +10% | +10% |
| Q1 2026 | $52.6M | -10% | +2% |
| Q3 2025 | $58.3M | +11% | — |
| Q2 2025 | $52.6M | +2% | — |
| Q1 2025 | $51.7M | — | — |
Q3 2026 at a glance
Collegium Pharmaceutical, Q3 2026: revenue $216M (+3% year over year), operating margin 13.3%, net earnings $21.8M, operating cash flow $86.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Collegium Pharmaceutical's Belbuca revenue?
Collegium Pharmaceutical's Belbuca revenue was $57.7M in Q3 2026 (third quarter 2026), +0.1% from Q2 2026.
How has Collegium Pharmaceutical's Belbuca revenue changed?
Over the last 6 quarters it ranged from $51.7M (Q1 2025) to $58.3M (Q3 2025).
Q3 2026 results → · How Collegium Pharmaceutical makes money →